Objective:To investigate the effect of rosiglitazone(RSG)on C reactive protein(CRP) induced growth,apoptosis and the expression of nuclear factor kappa B(NF-κB) in human umbilical vein endothelial cells(HUVECs),and explore the roles of rosiglitazone in the mechanism of anti-atherosclerosis. Methods:HUVECs cultured at the 5th generation were divided into eight groups:Normal control group(NG),CRP 5 μg/L group(CRP 5),CRP 20 μg/L group(CRP 20),CRP 100 μg/L group(CRP 100),RSG control group(RSG),RSG and CRP 5 group,RSG and CRP 20 group,RSG and CRP 100 group. Cells were intervened by RSG(5 μmol/L) for 12,24 and 48 hours. RT-PCR was used to detect the expression of NF-κB. The growth and apoptosis of HUVECs were also observed. Results:The expression of NF-κB and the apoptosis were obviously higher in the each mass concentration CRP group than that in the NG(P < 0.05), more obviously when the concentration was 100 μg/L(P < 0.05),and the growth change was opposite. The mRNA expression level of NF-κB and the apoptosis in cells treated by RSG were lower significantly than that of control group(P < 0.05),the growth was higher than that of control group,and it was significantly higher with the increase of the time. Conclusion:CRP promoted the apoptosis and inhibited the growth of Certain density CRP can induce the expression of NF-κB,which indicated that CRP can activate the inflammation response, and play a vital role in the pathology mechanism at coronal AS. Rosiglitazone can effectively reduce the inflammation effect of CRP thus to delay the occurrence of the AS.